Seeking Alpha

Synergy to initiate Phase 3 plecanatide CIC trial in Q4

  • Synergy Pharmaceuticals (SGYP) completes an end-of-Phase 2 meeting with the FDA regarding plecanatide for the treatment of chronic idiopathic constipation.
  • The company and the regulator reach an agreement on the requirements and specifications for a Phase 3 pivotal program which will begin in Q4. (PR)
  • Shares +3.26% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: